menu search

aerovate therapeutics presents nonclinical pharmacokinetic data in support of av-101, a novel dry powder inhaled formulation of imatinib, at the american thoracic society (ats) 2023 international conf

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impac...

May 22, 2023, 5:15 pm

aerovate: small mid-stage biotech targeting multibillion-dollar pah market

AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient...

April 12, 2023, 8:45 am

aerovate: developing an exciting pah drug, initiating with a buy

aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-1...

January 29, 2023, 7:12 am


Search within

Pages Search Results: